Taro to Pay Nearly $206 Million to Resolve Price-Fixing Allegations
- July 24, 2020
Generic drug company Taro Pharmaceuticals U.S.A., Inc. agreed to pay nearly a $206 million to settle criminal allegations that it conspired with other sellers to fix prices for numerous generic drugs, including medications for seizures, bipolar disorder, pain and arthritis, and skin conditions, the Department of Justice (DOJ) announced July 23.
ARTICLE TAGS
You must be logged in to access this content.